SEPTEMBER 25TH, 2024POSTED BY EMORY UNIVERSITY(Credit: Getty Images) TAGS DEPRESSIONMOTIVATIONUNIVERSITY EMORY UNIVERSITYAn anti-inflammatory drug shows promise in boosting motivation for people with depression, a new study reveals. Motivational impairments are a core component of depression and have long been linked with poor treatment outcomes, diminished quality of life, and heightened suicide risk. Growing evidence suggests...
Tag: <span>Drug</span>
Post
Scientists discover a new cardiovascular risk factor and identify a drug able to reduce its effects
August 30, 2024 by Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Summary of main findings by CNIC researchers. Clonal hematopoiesis and the expansion of blood cells carrying certain acquired mutations represent a new cause of atherosclerosis and cardiovascular disease, not a consequence of it. The effects of some of these mutations can be attenuated...
Post
Clinical trial shows rheumatoid arthritis drug could prevent disease
by King’s College London Credit: Unsplash/CC0 Public DomainA drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s College London, provide hope for arthritis sufferers after it was shown that the...
Post
Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer
by University of Ottawa Multi-omic characterization of VXN cancer-selective effect on cell functions. Credit: Nature Cancer (2024). DOI: 10.1038/s43018-024-00727-yA new, cutting-edge study from the University of Ottawa (uOttawa) has found vanoxerine, a drug initially developed for the treatment of cocaine addiction, could impede advanced colorectal cancer stem cells by essentially re-wiring critical gene networks. This new...
Post
Older Americans Are About to Lose a Lot of Weight
People over 65 make up a sizable portion of Americans on GLP-1 drugs. That might be trouble. By Daniel Engber A scale overlaid with a silhouette of an older adultIllustration by Ben Kothe / The Atlantic. Sources: Peter Dazeley; JakeOlimb / Getty.Imagine an older man goes in to see his doctor. He’s 72 years old...
Post
New anti-blood clotting drug may lower risk of recurrent strokes
by Olivia Dimmer, Northwestern University Credit: Wikimedia CommonsAn experimental drug designed to block blood-clotting proteins may lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology. More than 795,000 people in the United States each year suffer a stroke, according to the American Heart Association, and nearly 1 in 5...
Post
Significant benefit seen in Phase III trial of experimental drug for kidney disease
by University of Washington School of Medicine Credit: Pixabay/CC0 Public Domain In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria—albumin in urine, a sign of kidney damage—for 50% of participants. When the experimental drug was paired with a standard-care medication, 70% of participants reportedly experienced a significant reduction in...
Post
New Alzheimer’s drug shines light on need for assessments to head off ‘a tsunami of cognitive afflictions’
by University of Southern California Credit: Pixabay/CC0 Public Domain Two stories dominated Alzheimer’s news this year: The FDA’s approval of Leqembi, the first drug to slow progression of the disease, and a surprising study showing that mild cognitive impairment is wildly underdiagnosed. “For mild cognitive impairment, or MCI, caused by Alzheimer’s disease, the earlier you treat...
Post
Drug that kills off sleeping bone cells could treat lower back pain
by Emily Packer, eLife ABT263 effectively depletes endplate SnOCs in the LSI and aging mouse models.(a-c) Immunofluorescent staining of p16 (green), TRAP (red) and nuclei (DAPI; blue) of the endplates in aged (a) and LSI-mice (b) injected with PBS (control) or ABT263 and the quantitative analysis of SnOCs based on dual staining for p16 and TRAP...
Post
This Drug Works, but Wait Till You Hear What’s in It
F. Perry Wilson, MD, MSCEDISCLOSURES October 24, 2023 Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr F. Perry Wilson of the Yale School of Medicine. As some of you may know, I do a fair amount of clinical research developing and evaluating artificial intelligence (AI) models, particularly machine learning...